Small Cap Pharma Stock Fixes Record Date Dividend Payment, To Go Ex-Dividend On August 04

Small Pharmaceuticals company, Strides Pharma Science Ltd. on Friday, Jul 21, 2023, announced the record date for dividend. The Board fixed Aug 04, 2023, as the record date for 15% dividend i.e. Rs Rs 1.50 per share of Rs 10/-each for the financial year 2022-23.

The stock recommended the said dividend on May 25, 2023, in a Board meeing. The dividend will be paid within 30 days from the date shareholders' approval at the AGM of the company. The company has a market cap of Rs 3,975.13 Crore.

"As informed by the Company on May 25, 2023, Board of Directors have recommended a Dividend of Rs. 1.50/- per equity share of Rs. 10/- each (at the rate of 15%) for FY23. Record Date for the purpose of said Dividend is Friday, August 4, 2023. Dividend once approved by Shareholders in the ensuing AGM, shall be paid within 30 days from the date of such approval," the Board of Directors of Strides Pharma Science said in an exchange filing.

"Recommendation of final dividend of Rs. 1.50/- per equity share of Rs. 10/- each (at the rate of 15%) for financial year ended March 31, 2023. Dividend will be paid within 30 days from the date of Shareholders' approval at the ensuing Annual General Meeting (AGM) of the Company," the Board said in an exchange filing.

On Friday, the Strides Pharma Science shares closed 0.57% higher at Rs 440.20 with an intraday high of Rs 443.10 and an intraday low of Rs 436.40 on BSE. The stock traded its 52-week high at Rs 486.80 apiece and 52-week low at Rs 268.40 apiece, respectively.

The stock price jumped 1.101% in the past 1 week, while in 1 month it jumped 6.37%. In 3 and 6 months, it gained 34.97% and 33.98%, respectively. In 1 year, it gained 27.53%. In 3 years, it gained 7.39%. In 5 years, it gained 27.26%.

Disclaimer

The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.